New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

Core Insights - Alnylam Pharmaceuticals announced new post hoc analyses results from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic for treating cardiomyopathy and polyneuropathy associated with transthyretin-mediated amyloidosis [1] Company Overview - Alnylam Pharmaceuticals is recognized as a leading company in RNAi therapeutics, focusing on innovative treatments for rare diseases [1] Study Results - The HELIOS-B Phase 3 study specifically targets the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults [1]